HONG KONG – An international study led by the University of South Florida (USF) has revealed important new information regarding the critical genes of the deadly malarial parasite, Plasmodium falciparum, which could help investigators prioritize targets for future development of newer, more effective antimalarial drugs. Read More
HONG KONG – China's Asymchem Laboratories (Tianjin) Co. Ltd. joined hands with a top private equity firm and two government-backed parties to spearhead drug innovation in the northeastern city of Tianjin to bring novel drugs from overseas into the Chinese market. Read More
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong last week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China. Read More
PERTH, Australia – Industry stakeholders praised Australia's federal budget for 2018-2019, released late last week, because the government said it was seeing results from investments pumped into the medical technology and pharmaceuticals sector, and it will continue to invest more. Read More
DUBLIN – Takeda Pharmaceutical Co. Ltd. has convinced the board of Shire plc of the merits of its £46 billion (US$62.1 billion) cash-and-shares takeover offer. Now it must do likewise with Shire's investors – as well as its own. Read More
HONG KONG – Nasdaq-listed Chinese vaccine maker Sinovac Biotech Ltd. is on the brink of collapse, as it is undergoing a series of events due to internal disputes concerning its privatization. The company has put its vaccine productions on hold, which may soon have an impact on its business. Read More
SHANGHAI – Chinese antibody discovery biotech Mabspace Biosciences Co. Ltd., of Suzhou, has raised $40 million in series B financing to further pursue its immuno-oncology (I-O) ambitions. Founded in 2013, the startup has proved itself to be relatively careful with money. Its last round of financing was three years ago, when Mabspace raised $15 million from Lilly Asia Ventures (an independent venture fund, once a part of Eli Lilly and Co.). Read More
Wuxi Apptec Co. Ltd., of Shanghai, said it is listing its shares on the Shanghai Stock Exchange following the IPO of 104.1 million shares of common stock at ¥21.60 (US$3.39) each. The company plans to use the proceeds to build and expand its R&D facilities in China. Read More
